At least three irreversible EGFR-TKIs (neratinib (HKI-272), XL647, and PF-00299804) were used in phase II studies of NSCLC patients with acquired resistance to gefitinib or erlotinib (Rizvi et al, 2008; Janne et al, 2009; Sequist et al, 2010). Here, EGFR is linked to non-small cell lung carcinoma.